Doctors with life-saving Cambridge healthcare charity angry after government funding cuts cambridge-news.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cambridge-news.co.uk Daily Mail and Mail on Sunday newspapers.
Singapore based, Tzar Labs, a molecular diagnostic company, along with Mumbai-based Epigeneres Biotechnology, claimed an unprecedented breakthrough in early
Tzar Labs announces breakthrough in early-stage cancer with simple blood test
Tzar Labs announces breakthrough in early-stage cancer with simple blood test
Last Updated: Fri, May 7th, 2021, 19:20:20hrs
New Delhi, May 7 (IANS) Singapore based, Tzar Labs, a molecular diagnostic company, along with Mumbai-based Epigeneres Biotechnology, claimed an unprecedented breakthrough in early-detection and prognosis/diagnosis of cancer. This is possible with a novel blood test - a world-first - that can help determine whether cancer is absent, imminent, or present, and also detect different stages of the disease, a company statement said.
This will pave the way for widespread early detection and treatment of cancer, thereby potentially saving millions of lives. This innovation will redefine cancer diagnostics through precise and accurate detection before any symptoms or tumours develop, it said.
BBC News
Published
image captionHMP Whitemoor is a high-security prison for about 450 inmates
The death of a man serving life for two murders has prompted concern over a prison s dirty inpatient unit.
Alvin Black, 59, killed Timothy Nalty in 1995 and Johanna Czardebon in 1996, both in Bedfordshire.
He died at HMP Whitemoor, Cambridgeshire, in November 2019, and an ombudsman reported they heard a claim he refused to go to the inpatient unit over cleanliness concerns.
The Prison Service said it had since revised its cleaning schedule.
In 1997, Black, from Bedford, was convicted of murdering German tourist Ms Czardebon during an armed raid on the town s County Hotel.
Press release content from Business Wire. The AP news staff was not involved in its creation.
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
May 3, 2021 GMT
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
PARIS (BUSINESS WIRE) May 3, 2021
Regulatory News:
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that